Results Of Multicenter Comparative Study Of Safety And Efficacy Of The Drugs Leucostim? And Neupogen? In The Treatment And Prophylaxis Of Neutropenia In Children

L.G. Fechina, O.P. Hlebnikova, N.Yu. Shipovskaya, A.G. beznoschenko, O.B. Polushkina, O.V. Aleinikova, V.V. Lebedev, A.F. Karelin, E.V. Inushkina, L.P. Privalova, N.A. Popova, R.A. Ivanov, Yu.F. She, A.A. Maschan

Results of multicenter comparative study of safety and efficacy of the drugs Leucostim? and Neupogen? in the treatment and prophylaxis of neutropenia in children
The results of a multicenter randomized double-blind clinical trial with crossover design on evaluating the effectiveness of two preparations of recombinant human granulocyte colony-stimulating factor - Leykostim® and Neupogen® - for treatment and prevention of neutropenia associated with chemotherapy of malignant neoplasms in children are presented. The study included 40 children aged 2 months to 17 years (median - 9 years) with various malignant tumors and the presence of indications for chemotherapy. It is shown that Leykostim® and Neupogen® administrations at the dose of 5 mg/kg/day in children are highly effective for treatment and prevention of neutropenia associated with chemotherapy of malignant neoplasms in all age’s children. Drug Leykostim ® on efficacy and safety was equal to drug Neupogen ® and was well tolerated.

Keywords

Similar Articles